Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized - Takeaways - MDSpire

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized

  • By

  • Sumit Sharma

  • Phoebe Lin

  • Allen Hu

  • Eric B. Suhler

  • Meike Pauly-Evers

  • William Holmes

  • Zeinab Barekati

  • Daniela Willen

  • Lachlan Macgregor

  • Laura Steeples

  • Zdenka Haskova

  • Derrick Feenstra

  • David Silverman

  • Benedicte Passemard

  • Sascha Fauser

  • Marina Mesquida

  • May 1, 2026

  • 0 min

Share

  • 1

    Uveitic macular edema (UME) is a major cause of vision loss in noninfectious uveitis, often resistant to existing treatments.

  • 2

    Vamikibart is a novel intravitreal monoclonal antibody targeting IL-6, designed to minimize systemic exposure and adverse effects.

  • 3

    The DOVETAIL study is a phase 1 trial assessing the safety and efficacy of vamikibart in patients with UME secondary to noninfectious uveitis.

  • 4

    Participants in the DOVETAIL study received varying doses of vamikibart every four weeks, with a focus on evaluating pharmacokinetics and clinical outcomes.

  • 5

    Results from the DOVETAIL study indicate that vamikibart may provide a targeted therapeutic approach for managing UME.

Original Source(s)

Interleukin 6 Inhibition With Vamikibart for Uveitic Macular Edema: The Phase 1 DOVETAIL Nonrandomized

  • by Sumit Sharma, Phoebe Lin, Allen Hu, Eric B. Suhler, Meike Pauly-Evers, William Holmes, Zeinab Barekati, Daniela Willen, Lachlan Macgregor, Laura Steeples, Zdenka Haskova, Derrick Feenstra, David Silverman, Benedicte Passemard, Sascha Fauser, Marina Mesquida

  • May 1, 2026

Related Content

EULAR Updates Behçet’s Syndrome Recommendations

EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement

Effectiveness of Pars Plana Vitrectomy in Treating Symptomatic Vitreous Floaters Linked to Fuchs Heterochromic Iridocyclitis

Vamikibart Shows Early Safety in Uveitic Macular Edema

Phase 1 nonrandomized trial reported no drug-related serious adverse events, but efficacy remains unproven